Features | Partner Sites | Information | LinkXpress
Sign In
ElsMed
Agfa Healthcare
Schiller

“Fastener” Molecules Enhance MRI Contrast Agents

By Medimaging International staff writers
Posted on 04 Jun 2014
Image: Dr. Kong and others demonstrated that their fastener molecule readily inserted itself into the membrane of pre-made liposomes. Gadolinium stably associated with the modified nanoparticles in solution, and experiments in animal models showed that these nanoparticles produced clear diagnostic images (Photo courtesy of Janet Sinn-Hanlon, DesignGroup@VetMed, University of Illinois).
Image: Dr. Kong and others demonstrated that their fastener molecule readily inserted itself into the membrane of pre-made liposomes. Gadolinium stably associated with the modified nanoparticles in solution, and experiments in animal models showed that these nanoparticles produced clear diagnostic images (Photo courtesy of Janet Sinn-Hanlon, DesignGroup@VetMed, University of Illinois).
Biomedical scientists have increased the effectiveness of specific contrast agents that are frequently used for imaging blood vessels and internal bleeding by linking them with nanoparticles. The contrast agent being used is packaged inside or bonded to the surface of microscopic particles, which can be designed to target specific parts of the body or prolong the agent’s activity.

When associate professor of chemical and biomolecular engineering Dr. Hyunjoon Kong, graduate student Cartney Smith, and colleagues from the Institute for Genomic Biology, University of Illinois at Urbana-Champaign (USA) set out to improve magnetic resonance imaging (MRI) technology, they turned to current contrast agent technology inside out.

When clinicians perform an MRI scan, they administer a contrast agent: a compound that, when injected into the bloodstream or ingested by the patient just before the MRI, improves structure or organ clarity in the resulting image. One typical class of contrast agent, frequently used for imaging of blood vessels and internal bleeding, contains gadolinium, a rare-earth metal.

Recently, biomedical researchers have discovered ways to increase the effectiveness of certain contrast agents by associating them with nanoparticles. The contrast agent being used is packaged inside or bonded to the surface of microscopic particles, which can be designed to target certain regions of the body or prolong the agent’s activity. They are now examining the multipurpose use of nanoparticles. If particles could be loaded with several types of contrast agents or dyes instead of one, or a contrast agent along with another type of diagnostic aid or a medication, clinicians could more effectively test for and treat disorders, and limit the number of injections received by patients.

Similar to children sharing a new plaything, although, compounds packed together into a nanoparticle cannot always play well together. For instance, contrast agents may bind to other chemicals, reducing their effectiveness. Furthermore, when contrast agents are enclosed inside a nanoparticle, they may not work as well. Efforts to attach agents to the outer surface of nanoparticles by covalent formation are also challenging, as they can negatively affect the nanoparticle activity or the compounds that they carry.

Drs. Kong, Smith and colleagues attacked these challenges by using interactions between naturally occurring biomolecules as a guide. Many types of proteins are strongly attached to cell membranes not by covalent bonds, but by the sum of multiple weaker forces—the attraction of positive and negative charges, and the tendency of nonpolar (oil-like) compounds to seek each other and avoid water.

The group theorized that the same types of forces could be used to attach a contrast agent to the surface of a type of nanoparticle called a liposome, which resembles a little piece of cell membrane in the shape of a tiny bubble. The researchers designed a “fastener” molecule, DTPA-chitosan-g-C18, that is charged, attracting it to the liposome and binding it to the contrast agent gadolinium. A nonpolar region anchors it to the liposome membrane.

In a series of experiments reported October 2014 American Cancer Society’s journal ACS Nano article, Dr. Kong and coworkers demonstrated that their fastener molecule easily inserted itself into the membrane of pre-made liposomes. Gadolinium stably associated with the engineered nanoparticles in solution, and research in animal models revealed that these nanoparticles generated well-defined diagnostic images.

“The strategy works like Velcro on a molecular level to adhere functional units to the outer leaflet of a liposome,” said Dr. Smith, who was first author on the study. “This work represents a new material design strategy that is scalable and easily implemented. The development of improved contrast agents has the potential to directly impact patients’ lives by detecting damaged blood vessels.”

One of the difficulties of working with liposomes is their tendency to degrade inside the body. When the fastener-loaded liposomes degraded, some of the efficacy of the gadolinium was lost. In a second study published April 8, 2014, in the journal Langmuir, Drs. Kong and Smith developed a process for chemically cross-linking the components of the nanoparticle that prolonged the life of the nanoparticles in biologic environments.

Related Links:

Institute for Genomic Biology, University of Illinois at Urbana-Champaign



Channels

Radiography

view channel
Image: Agfa HealthCare’s DX-D Mobile Retrofit solution will allow hospitals an easy and affordable way to upgrade existing GE Healthcare’s AMX 4 and 4 plus mobile X-ray systems to direct radiography (DR) (Photo courtesy of Agfa Healthcare).

Retrofit Enables Cost-Effective Upgrade of Existing Mobile X-Ray Systems to Direct Radiography

A mobile retrofit system has been designed to be mounted on mobile X-ray systems to create an easy way for hospitals to go digital without having to replace existing mobile X-ray units. A direct radiography... Read more

Ultrasound

view channel
Image: Ultrasound image of the Circle of Willis (Photo courtesy of the Swedish Cerebrovascular Center, Seattle, WA, USA).

New Approaches for Transcanial Ultrasound Used for the Treatment of Brain Tumors and Targeted Drug Delivery

A study completed by a Finnish researcher provides new insights into the limitations and potential new directions for the future advancement of transcranial ultrasound therapy. Active research is ongoing... Read more

Nuclear medicine

view channel

PET/CT Using FDG-Labeled Leukocytes Detects Infection in Acute Pancreatitis Patients

A study out of India that identifies infection in patients with pancreatic fluid collections may rapidly and effectively rule out active infection in the body. This treatment may help in making nuclear medicine imaging a mainstay in clinical management practices. Acute pancreatitis (AP) is an abrupt inflammation of the pancreas.... Read more

General/Advanced Imaging

view channel

Diagnostic Imaging Tests Ordered by General Practitioners in Australia Nearly Double in 10 Years

A 45% increase in diagnostic imaging tests ordered by Australian general practitioners (GPs) is being fueled by increasing GP visits, an escalating number of problems managed at doctor visits, and a higher probability that GPs order imaging tests for these problems, according to a new study. Based on a long-term national... Read more

Imaging IT

view channel
Image: An X-ray using the ClearRead bone suppression software technology (Photo courtesy of Riverain Technologies).

Bone Suppression Software Used to Optimize Diagnostic Capability of X-Ray Systems

Clinicians are gathering important information from the most routine imaging exam, the chest X-ray, by using advanced software that enhances X-ray images captured by the equipment they already have or... Read more

Industry News

view channel

Acquisition Includes Radiation Simulation Software for Radiotherapy Applications

Varian Medical Systems, Inc. (Palo Alto, CA, USA) has acquired certain assets of Transpire, Inc. (Gig Harbor, WA, USA) including the Acuros dose calculation software, which has been incorporated into Varian’s BrachyVision and Eclipse treatment planning software systems. The acquisition closed at the end of July 2014.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.